Quantinuum (QNT) Could Be 56% Undervalued On Mixed Valuation Signals

Quantinuum (QNT) has drawn fresh attention after appointing Robin Schulman as Chief Legal Officer and Rory O’Byrne as Chief People Officer, expanding its senior leadership team in the middle of an active year for the stock.

See our latest analysis for Quantinuum.

Against that backdrop, Quantinuum’s 1-day share price return of 1.03% contrasts with a 7-day share price return that declined 7.88% and a 30-day share price return that fell 30.09%. The year-to-date share price return is down 12.5%, pointing to fading momentum despite recent partnership and leadership headlines.

If you are watching Quantinuum’s moves and want more quantum exposure, now could be a time to scan the market using the 26 quantum computing stocks.

Quantinuum now trades at a clear discount to both analyst targets and one intrinsic value estimate after a sharp pullback. The gap between the price, at $52.83, and those benchmarks is what the valuation work needs to explain next.

Advertisement

Preferred Price-to-Book of 68.7x: Is it justified?

Quantinuum’s valuation story is split. Our DCF work suggests a large discount to estimated future cash flows, while the preferred multiple, P/B, flags a very high price tag relative to both peers and the wider US IT sector.

The P/B ratio compares a company’s market value to the book value of its equity. For Quantinuum, that figure sits at 68.7x, versus a peer average of 40.1x and a US IT industry average of 3x. For a business still reporting a net loss of $298.665 million on revenue of $17.083 million, that is a rich multiple anchored more in expectations than current financials.

Analysts also sit well above the current $52.83 share price with a $98.75 target, yet their views are not tightly clustered. That weak agreement means there is less collective conviction behind those targets. This adds another layer of uncertainty around how much investors are willing to pay for Quantinuum’s quantum computing platform today.

In practical terms, paying a P/B of 68.7x when the sector sits at 3x suggests the market is assigning a premium that is many times higher than typical IT stocks. If future execution and adoption do not line up closely with these expectations, that gap could be difficult to justify compared with companies priced nearer to book value or closer to the sector norm. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 68.7x (OVERVALUED)

However, Quantinuum still faces clear risks, including ongoing net losses against modest revenue and a P/B multiple that could compress quickly if sentiment weakens.

Find out about the key risks to this Quantinuum narrative.

Another View on Quantinuum’s Value

While Quantinuum looks expensive on a P/B of 68.7x, the SWS DCF model points the other way. At a share price of $52.83 and a future cash flow value estimate of $120.30, the stock screens as undervalued using this method. Which signal should carry more weight for you as an investor?

Look into how the SWS DCF model arrives at its fair value.

QNT Discounted Cash Flow as at Jul 2026
QNT Discounted Cash Flow as at Jul 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Quantinuum for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Quantinuum pulling mixed signals on value and risk, it makes sense to move quickly and ground your own view in the underlying data. To see both sides of that picture in one place, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Quantinuum?

If Quantinuum has your attention, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that could fit your portfolio style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Quantinuum might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:QNT

Quantinuum

Manufactures and develops quantum computing hardware and software in United States and Internationally.

Flawless balance sheet and slightly overvalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

CL
Clive_Thompson
6831 logo
Clive_Thompson on Green Tea Group ·

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend

Fair Value:HK$8.728.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AZ
PRG logo
aziz_22khi on PRG Holdings Berhad ·

WHERE DID THE SIX MILLION SHARES GO? THE PRG OWNERSHIP TRAIL INVESTORS CANNOT IGNORE

Fair Value:RM 0.4477.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
86 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
195 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0